Cargando…

The Spectrum of Co-Diagnoses in Patients with Colorectal Cancer: A Retrospective Cohort Study of 17,824 Outpatients in Germany

SIMPLE SUMMARY: We identified a panel of co-diagnosis occurring at higher or lower frequencies in CRC patients compared to matched controls without CRC. Such data might help optimizing CRC screening and improving the clinical management of CRC patients. ABSTRACT: Background: The prognosis of colorec...

Descripción completa

Detalles Bibliográficos
Autores principales: Loosen, Sven H., Schöler, David, Labuhn, Simon, Mertens, Alexander, Jördens, Markus S, Luedde, Mark, Kostev, Karel, Luedde, Tom, Roderburg, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367470/
https://www.ncbi.nlm.nih.gov/pubmed/35954488
http://dx.doi.org/10.3390/cancers14153825
_version_ 1784765814191161344
author Loosen, Sven H.
Schöler, David
Labuhn, Simon
Mertens, Alexander
Jördens, Markus S
Luedde, Mark
Kostev, Karel
Luedde, Tom
Roderburg, Christoph
author_facet Loosen, Sven H.
Schöler, David
Labuhn, Simon
Mertens, Alexander
Jördens, Markus S
Luedde, Mark
Kostev, Karel
Luedde, Tom
Roderburg, Christoph
author_sort Loosen, Sven H.
collection PubMed
description SIMPLE SUMMARY: We identified a panel of co-diagnosis occurring at higher or lower frequencies in CRC patients compared to matched controls without CRC. Such data might help optimizing CRC screening and improving the clinical management of CRC patients. ABSTRACT: Background: The prognosis of colorectal cancer (CRC) patients is determined to a decisive extent by comorbidities. On the other hand, anti-cancer treatments for CRC are associated with relevant toxicities and may therefore cause additional comorbidities. Methods: This retrospective cohort study assessed the prevalence of various diseases in patients 12 months before and 12 months after an initial diagnosis of colorectal cancer (ICD-10: C18, C20) in 1274 general practices in Germany between January 2000 and December 2018. The study is based on the Disease Analyzer database (IQVIA), which contains drug prescriptions, diagnoses, and basic medical and demographic data. Patients with and without CRC were matched by sex, age, and index year. Results: We identified several diagnoses with a significantly higher prevalence among CRC patients 12 months prior to the index date compared to controls. These diagnoses included gastrointestinal hemorrhage, hemorrhoids, perianal venous thrombosis, and abdominal and pelvic pain, as well as functional intestinal disorders. In contrast, the prevalence of lipid metabolism disorder, depression, hypertension, coronary heart disease, or acute bronchitis was significantly lower in CRC cases. After diagnosis of CRC, we found a significantly higher prevalence of anemia, polyneuropathies, functional intestinal disorders, and chronic kidney disease among CRC patients compared to the control group, while the prevalence of acute upper respiratory infections of multiple and unspecified sites and acute bronchitis was significantly lower in CRC patients compared to non-CRC patients. Conclusions: In the present study, we identified a variety of diseases occurring at higher or lower frequencies in CRC patients compared to matched controls without CRC. This might help to select patients for early CRC screening and improve the clinical management of CRC patients.
format Online
Article
Text
id pubmed-9367470
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93674702022-08-12 The Spectrum of Co-Diagnoses in Patients with Colorectal Cancer: A Retrospective Cohort Study of 17,824 Outpatients in Germany Loosen, Sven H. Schöler, David Labuhn, Simon Mertens, Alexander Jördens, Markus S Luedde, Mark Kostev, Karel Luedde, Tom Roderburg, Christoph Cancers (Basel) Article SIMPLE SUMMARY: We identified a panel of co-diagnosis occurring at higher or lower frequencies in CRC patients compared to matched controls without CRC. Such data might help optimizing CRC screening and improving the clinical management of CRC patients. ABSTRACT: Background: The prognosis of colorectal cancer (CRC) patients is determined to a decisive extent by comorbidities. On the other hand, anti-cancer treatments for CRC are associated with relevant toxicities and may therefore cause additional comorbidities. Methods: This retrospective cohort study assessed the prevalence of various diseases in patients 12 months before and 12 months after an initial diagnosis of colorectal cancer (ICD-10: C18, C20) in 1274 general practices in Germany between January 2000 and December 2018. The study is based on the Disease Analyzer database (IQVIA), which contains drug prescriptions, diagnoses, and basic medical and demographic data. Patients with and without CRC were matched by sex, age, and index year. Results: We identified several diagnoses with a significantly higher prevalence among CRC patients 12 months prior to the index date compared to controls. These diagnoses included gastrointestinal hemorrhage, hemorrhoids, perianal venous thrombosis, and abdominal and pelvic pain, as well as functional intestinal disorders. In contrast, the prevalence of lipid metabolism disorder, depression, hypertension, coronary heart disease, or acute bronchitis was significantly lower in CRC cases. After diagnosis of CRC, we found a significantly higher prevalence of anemia, polyneuropathies, functional intestinal disorders, and chronic kidney disease among CRC patients compared to the control group, while the prevalence of acute upper respiratory infections of multiple and unspecified sites and acute bronchitis was significantly lower in CRC patients compared to non-CRC patients. Conclusions: In the present study, we identified a variety of diseases occurring at higher or lower frequencies in CRC patients compared to matched controls without CRC. This might help to select patients for early CRC screening and improve the clinical management of CRC patients. MDPI 2022-08-06 /pmc/articles/PMC9367470/ /pubmed/35954488 http://dx.doi.org/10.3390/cancers14153825 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Loosen, Sven H.
Schöler, David
Labuhn, Simon
Mertens, Alexander
Jördens, Markus S
Luedde, Mark
Kostev, Karel
Luedde, Tom
Roderburg, Christoph
The Spectrum of Co-Diagnoses in Patients with Colorectal Cancer: A Retrospective Cohort Study of 17,824 Outpatients in Germany
title The Spectrum of Co-Diagnoses in Patients with Colorectal Cancer: A Retrospective Cohort Study of 17,824 Outpatients in Germany
title_full The Spectrum of Co-Diagnoses in Patients with Colorectal Cancer: A Retrospective Cohort Study of 17,824 Outpatients in Germany
title_fullStr The Spectrum of Co-Diagnoses in Patients with Colorectal Cancer: A Retrospective Cohort Study of 17,824 Outpatients in Germany
title_full_unstemmed The Spectrum of Co-Diagnoses in Patients with Colorectal Cancer: A Retrospective Cohort Study of 17,824 Outpatients in Germany
title_short The Spectrum of Co-Diagnoses in Patients with Colorectal Cancer: A Retrospective Cohort Study of 17,824 Outpatients in Germany
title_sort spectrum of co-diagnoses in patients with colorectal cancer: a retrospective cohort study of 17,824 outpatients in germany
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367470/
https://www.ncbi.nlm.nih.gov/pubmed/35954488
http://dx.doi.org/10.3390/cancers14153825
work_keys_str_mv AT loosensvenh thespectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT scholerdavid thespectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT labuhnsimon thespectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT mertensalexander thespectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT jordensmarkuss thespectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT lueddemark thespectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT kostevkarel thespectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT lueddetom thespectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT roderburgchristoph thespectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT loosensvenh spectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT scholerdavid spectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT labuhnsimon spectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT mertensalexander spectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT jordensmarkuss spectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT lueddemark spectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT kostevkarel spectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT lueddetom spectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany
AT roderburgchristoph spectrumofcodiagnosesinpatientswithcolorectalcanceraretrospectivecohortstudyof17824outpatientsingermany